Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX

Abstract

CZP 400 mg every 4 weeks plus MTX was administred to paetints with rheumatid arthritis. ACR20 response rates were 45.9% vs 22.9% in patients treated only with methotrexate.

Keywords

• ANTITUMOR NECROSIS FACTOR
• RHEUMATOID-ARTHRITIS
• CONCOMITANT METHOTREXATE
• MONOCLONAL-ANTIBODY
• TRIAL
• IMPROVEMENT
• ETANERCEPT
• ADALIMUMAB
• OUTCOMES
• THERAPY